Pfizer has told the Indian government it wants to produce its Covid-19 vaccine locally if assured of faster regulatory clearance and freedom on pricing and exports, according to Reuters.
The US company pulled an application last month seeking emergency approval for its product in India after the drug regulator declined its request to skip a small local safety trial. That has kept its vaccine, developed with Germany’s BioNTech SE, out of one of the world’s biggest drug markets.
While withdrawing its application in early February, Pfizer said it would again seek emergency use approval to launch its Covid-19 vaccine in India, and would provide more data as it becomes available.
